Literature DB >> 8872500

Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro.

J Li1, S Gyorffy, S Lee, C S Kwok.   

Abstract

Human neutrophils were demonstrated to possess interleukin-2 receptor (IL-2R) beta and gamma chains, not alpha chain and the binding of IL-2 to the IL-2R beta chain on neutrophils plays an important regulatory role in neutrophil functions. We have investigated in this study the hypothesis that recombinant human IL-2 (rhIL-2) can directly activate human neutrophils and increase their adherence to human umbilical vein endothelial cells (HUVEC). In an in vitro microtiter adherence assay, rhIL-2 significantly stimulated neutrophil adherence to HUVEC in a dose- and time-dependent manner, rhILI-2 concentration at 2000 u/ml and 2 hour incubation gave the best neutrophil stimulation. Treatment of neutrophils with rhIL-2 increased the expression of adhesion molecule CD18. Pretreatment of the stimulated neutrophils with a blocking monoclonal antibody to CD18 decreased but not completely blocked the adherence of neutrophils to HUVEC. These data suggest than rhIL-2 can directly stimulate and increase neutrophil adherence to HUVEC by enhancing the expression of CD18 and possibly other adhesion molecules on neutrophil surface. This may be a critical step in the early stage of the vascular leak syndrome (VLS) associated with high dose IL-2 therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872500     DOI: 10.1007/bf01486739

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  30 in total

1.  Expression of the IL-2 receptor gamma chain on various populations in human peripheral blood.

Authors:  N Ishii; T Takeshita; Y Kimura; K Tada; M Kondo; M Nakamura; K Sugamura
Journal:  Int Immunol       Date:  1994-08       Impact factor: 4.823

2.  Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells.

Authors:  D Kotasek; G M Vercellotti; A C Ochoa; F H Bach; J G White; H S Jacob
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

3.  The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit.

Authors:  A J Grant; E Roessler; G Ju; M Tsudo; K Sugamura; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

4.  Activation of tumor necrosis factor-alpha production from human neutrophils by IL-2 via IL-2-R beta.

Authors:  S Wei; D K Blanchard; J H Liu; W J Leonard; J Y Djeu
Journal:  J Immunol       Date:  1993-03-01       Impact factor: 5.422

5.  Interleukin-2 (IL-2) activated natural killer (A-NK) cells: binding to microvascular endothelial cells and BRM enhancement of cytolytic activity.

Authors:  K W Brunson; M Ohashi; C A Miller; R P Kitson; P H Basse; R H Goldfarb
Journal:  In Vivo       Date:  1994 Jan-Feb       Impact factor: 2.155

6.  The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation.

Authors:  F D Moore; D D Schoof; M Rodrick; T J Eberlein
Journal:  Int J Cancer       Date:  1991-10-21       Impact factor: 7.396

7.  Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase.

Authors:  K Frasier-Scott; H Hatzakis; D Seong; C M Jones; K K Wu
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

9.  Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.

Authors:  J H Stevens; P O'Hanley; J M Shapiro; F G Mihm; P S Satoh; J A Collins; T A Raffin
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

10.  Alterations of neutrophil responses to tumor necrosis factor alpha and interleukin-8 following human endotoxemia.

Authors:  J S Solomkin; R C Bass; H S Bjornson; C J Tindal; G F Babcock
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more
  5 in total

1.  On-chip evaluation of neutrophil activation and neutrophil-endothelial cell interaction during neutrophil chemotaxis.

Authors:  Donghyuk Kim; Christy L Haynes
Journal:  Anal Chem       Date:  2013-10-28       Impact factor: 6.986

2.  Neutrophil chemotaxis within a competing gradient of chemoattractants.

Authors:  Donghyuk Kim; Christy L Haynes
Journal:  Anal Chem       Date:  2012-06-28       Impact factor: 6.986

3.  Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase.

Authors:  John D Miller; Suzanne E Clabaugh; Deandra R Smith; R Brian Stevens; Lucile E Wrenshall
Journal:  Immunol Cell Biol       Date:  2011-05-24       Impact factor: 5.126

4.  A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.

Authors:  R Brian Stevens; Kirk W Foster; Clifford D Miles; James T Lane; Andre C Kalil; Diana F Florescu; John P Sandoz; Theodore H Rigley; Kathleen J Nielsen; Jill Y Skorupa; Anna M Kellogg; Tamer Malik; Lucile E Wrenshall
Journal:  Transplantation       Date:  2015-01       Impact factor: 4.939

Review 5.  The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer.

Authors:  Natasha Ustyanovska Avtenyuk; Nienke Visser; Edwin Bremer; Valerie R Wiersma
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.